When a Statin Is Recommended Before the Full Picture Is Clear: A More Personalized Approach to Heart Health
Understanding Statin Recommendations and Cardiovascular Risk
Every week, I speak with patients who are trying to make sense of a cardiovascular recommendation they’ve been given.
Sometimes they’ve already been started on a statin.
Sometimes they’ve been told they need one—but haven’t started yet.
And often, they’re left wondering:
“How serious is this really—and how did we get here?”
This is not a conversation about avoiding statins. They absolutely have a role, and in the right context, they can meaningfully reduce cardiovascular risk.
But it is a conversation about context, sequencing, and understanding cardiovascular risk more clearly before committing to a long-term plan.
Where Most Patients Actually Start
Most patients don’t come in with advanced imaging or a clearly defined baseline.
Instead, they come in with:
- A standard lipid panel
- A recommendation for a statin
- Very little discussion of what may be driving their cardiovascular risk in the first place
Occasionally, someone has had imaging—most often a coronary artery calcium (CAC) score—and if that score is zero, they’re reassured that everything is fine.
But that’s not always the full picture.
A CAC score detects calcified plaque, which is generally more stable. What it does not detect is soft, non-calcified plaque, which is often more metabolically active and more closely associated with acute cardiovascular events.
This is one of the reasons why a CAC score of zero does not necessarily mean zero risk—particularly in younger patients and in women.
Why Cardiovascular Risk Calculators Don’t Tell the Whole Story
Most commonly used cardiovascular risk calculators in primary care are based on population-level data—using factors like age, cholesterol, blood pressure, and smoking status to estimate risk over time.
While helpful, these tools don’t account for more individualized factors such as ApoB, lipoprotein(a), metabolic health, or direct visualization of plaque.
As a result, decisions are often made based on statistical estimates rather than a more complete picture of an individual’s actual cardiovascular health.
A Shift Toward Personalized Cardiovascular Risk Assessment
One of the most meaningful shifts happening in cardiovascular care is a move toward more personalized and precise risk assessment.
Newer tools, such as AI-assisted coronary CT analysis (like Cleerly), allow us to go beyond simply identifying whether plaque is present. These technologies can help characterize:
- The type of plaque (calcified vs non-calcified)
- The total plaque burden
- How plaque changes over time
This allows for a much more individualized understanding of cardiovascular disease—and a way to track whether interventions are actually improving risk.
Lipids: More Than Just LDL Cholesterol
Traditional cholesterol panels are helpful, but they don’t always tell the full story.
Markers such as:
ApoB (Apolipoprotein B)
Lipoprotein(a)
are increasingly recognized as more accurate indicators of cardiovascular risk.
ApoB reflects the number of atherogenic particles—particles capable of promoting plaque formation within the arteries. This often provides a clearer picture of risk than LDL cholesterol alone, especially in patients with insulin resistance.
Lipoprotein(a) is largely genetically determined and can significantly influence baseline cardiovascular risk, regardless of lifestyle.
Lifestyle and Cardiovascular Risk Reduction
One of the most important—and often overlooked—truths in cardiovascular care is that lifestyle interventions are foundational, not optional.
Research consistently demonstrates meaningful impact:
- A Mediterranean-style diet reduced major cardiovascular events by approximately 30%
https://www.nejm.org/doi/full/10.1056/NEJMoa1800389 - Regular physical activity is associated with a 20–30% reduction in cardiovascular mortality
- In the Diabetes Prevention Program, lifestyle intervention reduced progression to diabetes by 58%
https://www.nejm.org/doi/full/10.1056/NEJMoa012512
Given how strongly insulin resistance contributes to atherosclerosis, these changes are not secondary—they are central to long-term cardiovascular health.
The Statin Conversation: A More Balanced Perspective
Statins have been shown in many studies to reduce cardiovascular risk—often cited in the range of 20–30% relative risk reduction—though the degree of benefit varies depending on the individual and their baseline risk.
They can also play a role in stabilizing plaque.
But like any medication, they are not without potential side effects.
Some patients experience:
- Muscle symptoms
- Fatigue
- Changes in blood sugar
- Neurologic symptoms
One of the more challenging patterns I see is when multiple medications are started at the same time—often a statin alongside something like thyroid support. When new symptoms arise, it becomes difficult to determine what is helping and what may not be tolerated.
When “Worse” Imaging May Not Be Worse
One important concept that is rarely explained to patients:
Interventions that improve cardiovascular risk—whether pharmacologic or lifestyle-based—can sometimes make imaging appear “worse” in the short term.
Statins, for example, are known to:
- Reduce softer, more vulnerable plaque
- Promote a shift toward more calcified, stable plaque
This can lead to an increase in coronary artery calcium score over time, even as overall cardiovascular risk is improving.
In other words:
An increase in calcification is not always a sign of disease progression—it may reflect plaque stabilization.
Why Sequencing Matters in Cardiovascular Care
In many cases, a more thoughtful approach to cardiovascular prevention might include:
- Establishing a baseline
- Addressing underlying contributors (such as metabolic health or thyroid function)
- Implementing targeted lifestyle changes
- Then layering in medication if needed
This allows for better clarity, improved tolerance, and more sustainable long-term outcomes.
Why Time Horizon Matters in Heart Health Decisions
One of the biggest drivers of anxiety is the sense that something must be done immediately.
But cardiovascular disease develops over years to decades.
In many cases, taking time to:
- Understand your risk
- Evaluate your response to treatment
- Make a more informed decision
does not meaningfully change short-term risk—but can significantly improve long-term outcomes.
A More Personalized Approach to Heart Health
This is not about rejecting conventional care.
It’s about expanding the conversation.
It’s about:
- Using better tools
- Asking better questions
- Creating a plan that is both evidence-based and individualized
The goal is not to choose between lifestyle and medication.
It is to understand how they work together—and when each is most appropriate.
The Takeaway
If you’ve been told you need a statin:
- Take it seriously—but don’t panic
- Ask what your true cardiovascular risk over time actually is
- Understand that not all plaque is the same
- Know that lifestyle changes have measurable impact
- And if something doesn’t feel right, it’s okay to ask questions
The best preventative care is not rushed.
It is thoughtful, informed, and personalized.
About the Author
Dr. Sarah Giardenelli is a naturopathic doctor and acupuncturist at Collective Health Center in Leesburg, VA. She focuses on a personalized, root-cause approach to care—helping patients better understand their health, interpret lab results in context, and make thoughtful, individualized decisions around prevention and approach to care. Her work often includes advanced cardiovascular risk assessment, metabolic health support, and integrative care for complex conditions.
Photo by Sasun Bughdaryan on Unsplash
